(ALC) Alcon - Overview
Stock: Intraocular Lenses, Contact Lenses, Surgical Equipment, Eye Drops, Vision
| Risk 5d forecast | |
|---|---|
| Volatility | 24.6% |
| Relative Tail Risk | -6.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.45 |
| Alpha | -21.43 |
| Character TTM | |
|---|---|
| Beta | 0.733 |
| Beta Downside | 0.704 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.24% |
| CAGR/Max DD | 0.10 |
EPS (Earnings per Share)
Revenue
Description: ALC Alcon January 28, 2026
Alcon Inc. (NYSE:ALC) is a global eye-care company that designs, manufactures, and distributes surgical and vision-care products. It operates through two segments-Surgical (cataract, vitreoretinal, and refractive-surgery equipment and consumables) and Vision Care (contact lenses, ocular-health pharmaceuticals, and related accessories). The product portfolio includes high-tech cataract platforms (Centurion, LenSx, NGENUITY), a range of intra-ocular lenses (monofocal, toric, presbyopia-correcting), vitreoretinal instruments, and LASIK systems (WaveLight, Contoura Vision), as well as daily disposable and color-enhancing contact lenses and dry-eye therapies.
Key recent metrics (FY 2025): revenue $8.2 billion, up 5.3 % YoY; operating margin 18.1 % (stable despite supply-chain pressures); R&D spend 7.2 % of sales, reflecting continued investment in premium surgical platforms. The global cataract surgery market is projected to grow at a 4.5 % CAGR through 2030, driven by aging demographics and increasing adoption of premium IOLs-a tailwind for Alcon’s Surgical segment.
Sector drivers include the rise in myopia prevalence (estimated 2.5 billion affected worldwide by 2030) boosting contact-lens demand, and the expansion of outpatient ophthalmic procedures that favor integrated surgical systems. Alcon’s recent FDA clearance for an AI-enhanced intra-operative measurement device (ORA 3.0) could further differentiate its offering, though adoption rates remain uncertain.
For a deeper quantitative assessment, you may want to explore Alcon’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 1.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.49 > 1.0 |
| NWC/Revenue: 32.79% < 20% (prev 39.58%; Δ -6.79% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.05b > Net Income 1.05b |
| Net Debt (3.74b) to EBITDA (1.77b): 2.11 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (495.9m) vs 12m ago -0.36% < -2% |
| Gross Margin: 55.12% > 18% (prev 0.55%; Δ 5457 % > 0.5%) |
| Asset Turnover: 32.93% > 50% (prev 32.15%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: 3.76 > 6 (EBITDA TTM 1.77b / Interest Expense TTM 199.8m) |
Beneish M -2.96
| DSRI: 1.07 (Receivables 1.94b/1.74b, Revenue 10.19b/9.76b) |
| GMI: 1.01 (GM 55.12% / 55.50%) |
| AQI: 1.01 (AQ_t 0.64 / AQ_t-1 0.63) |
| SGI: 1.04 (Revenue 10.19b / 9.76b) |
| TATA: -0.03 (NI 1.05b - CFO 2.05b) / TA 31.49b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of ALC shares?
Over the past week, the price has changed by +0.47%, over one month by +0.27%, over three months by +0.75% and over the past year by -11.92%.
Is ALC a buy, sell or hold?
- StrongBuy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.8 | 15.9% |
| Analysts Target Price | 91.8 | 15.9% |
| ValueRay Target Price | 79.2 | -0.1% |
ALC Fundamental Data Overview February 11, 2026
P/E Forward = 22.5225
P/S = 3.7975
P/B = 1.6792
P/EG = 2.1384
Revenue TTM = 10.19b USD
EBIT TTM = 751.7m USD
EBITDA TTM = 1.77b USD
Long Term Debt = 4.54b USD (from longTermDebt, last fiscal year)
Short Term Debt = 648.3m USD (from shortTermDebt, last quarter)
Debt = 5.23b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.74b USD (from netDebt column, last quarter)
Enterprise Value = 42.42b USD (38.68b + Debt 5.23b - CCE 1.50b)
Interest Coverage Ratio = 3.76 (Ebit TTM 751.7m / Interest Expense TTM 199.8m)
EV/FCF = 27.67x (Enterprise Value 42.42b / FCF TTM 1.53b)
FCF Yield = 3.61% (FCF TTM 1.53b / Enterprise Value 42.42b)
FCF Margin = 15.05% (FCF TTM 1.53b / Revenue TTM 10.19b)
Net Margin = 10.28% (Net Income TTM 1.05b / Revenue TTM 10.19b)
Gross Margin = 55.12% ((Revenue TTM 10.19b - Cost of Revenue TTM 4.57b) / Revenue TTM)
Gross Margin QoQ = 55.78% (prev 53.47%)
Tobins Q-Ratio = 1.35 (Enterprise Value 42.42b / Total Assets 31.49b)
Interest Expense / Debt = 0.97% (Interest Expense 51.0m / Debt 5.23b)
Taxrate = 16.25% (46.0m / 283.0m)
NOPAT = 629.5m (EBIT 751.7m * (1 - 16.25%))
Current Ratio = 2.12 (Total Current Assets 6.33b / Total Current Liabilities 2.99b)
Debt / Equity = 0.24 (Debt 5.23b / totalStockholderEquity, last quarter 22.06b)
Debt / EBITDA = 2.11 (Net Debt 3.74b / EBITDA 1.77b)
Debt / FCF = 2.44 (Net Debt 3.74b / FCF TTM 1.53b)
Total Stockholder Equity = 21.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.39% (Net Income 1.05b / Total Assets 31.49b)
RoE = 4.77% (Net Income TTM 1.05b / Total Stockholder Equity 21.93b)
RoCE = 2.84% (EBIT 751.7m / Capital Employed (Equity 21.93b + L.T.Debt 4.54b))
RoIC = 2.37% (NOPAT 629.5m / Invested Capital 26.58b)
WACC = 7.69% (E(38.68b)/V(43.91b) * Re(8.62%) + D(5.23b)/V(43.91b) * Rd(0.97%) * (1-Tc(0.16)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.27%
[DCF Debug] Terminal Value 82.27% ; FCFF base≈1.45b ; Y1≈1.79b ; Y5≈3.05b
Fair Price DCF = 104.3 (EV 54.99b - Net Debt 3.74b = Equity 51.26b / Shares 491.2m; r=7.69% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -11.69 | EPS CAGR: -47.05% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.85 | Revenue CAGR: 5.36% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.83 | Chg30d=+0.002 | Revisions Net=-4 | Analysts=10
EPS next Year (2026-12-31): EPS=2.19 | Chg30d=-0.029 | Revisions Net=-1 | Growth EPS=+3.5% | Growth Revenue=+7.1%